Migraine Attack Pain Phase Prediction Study

NCT ID: NCT06459635

Last Updated: 2024-06-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

70 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-09

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study of the ability to predict pain in a migraine attack, through premonitory symptoms and through an ambulatory monitoring device through real-time recording of hemodynamic variables, is one of the strategic lines of research of the unit. of Headaches at the Hospital de La Princesa since 2013 together with the Complutense and Polytechnic University of Madrid. Their results have been reflected in various publications (Pagán J, et al. Sensors 2015; Gago-Veiga AB, et al. J Pain Res 2018) and have promoted the creation of several invention patents.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with episodic migraine will be recruited from the monographic headache clinics of the 7 centers participating in the study. These patients, for a maximum period of 2 months, must monitor their hemodynamic variables with a wearable device and record all the clinical characteristics of their migraine attacks. Subsequently, with these records, an individualized algorithm will be created for each patient that aims to predict the onset of the migraine attack.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine Migraine Headache Migraine Disorders Migraine Without Aura Migraine With Aura

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with episodic migraine

Patients with episodic migraine who present between 4 and 10 migraine attacks per month. These patients must have a diagnosis of migraine by a headache neurologist and according to the criteria proposed by ICHD-3. In addition, they must present at least 1 year of evolution of the migraine, as well as a normal neurological examination and have given their informed consent.

No interventions assigned to this group

Control patients

People who have never had a headache episode with migraine characteristics. These may present, at most, one episode per month of headache with non-migraine characteristics in the last 3 months. In turn, they should not have a family history of migraine (1st and 2nd degree).

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 15 years and 69 years.
* Diagnosed with migraine by a headache neurologist and according to the criteria proposed by ICHD-3.
* History of migraine of at least 1 year of evolution.
* Normal neurological examination.
* Have given your informed consent.
* Be able to describe your clinical situation and the characteristics of your headache.
* Have an average of 10 to 14 migraine days per month in the three months prior to inclusion (high-frequency episodic migraine).
* User-level management capacity of "smartphone" type electronic devices.
* Be able to complete two months of study follow-up.

Exclusion Criteria

* Presence of another type of headache, with the exception of headache due to excessive use of analgesic medication.
* Cognitive deficiency or any other pathology that may prevent or make it difficult for the patient to perform the study correctly.
* Neurological focus in the examination.
* Pregnancy or breastfeeding period.
* Patients with known heart disease or bronchopathy, Sjögren\'s syndrome, diabetes mellitus, or hypo/hyperthyroidism.
* Carriers of pacemakers, neurostimulators or any other electronic device that is considered to make the interpretation of biometric records difficult.
* Anatomical problem that makes the use of the device impossible.
* Patients in whom it is expected that a change in migraine preventive treatment or other usual treatment will be possible during the study period.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Vall d'Hebron

OTHER

Sponsor Role collaborator

Hospital Donostia

OTHER

Sponsor Role collaborator

Hospital Universitario Marqués de Valdecilla

OTHER

Sponsor Role collaborator

Hospital Clínico Universitario Lozano Blesa

OTHER

Sponsor Role collaborator

Hospital Universitario La Fe

OTHER

Sponsor Role collaborator

Hospital Clínico Universitario de Valladolid

OTHER

Sponsor Role collaborator

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ana Beatriz Gago Veiga

Role: PRINCIPAL_INVESTIGATOR

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Universitario de La Princesa

Madrid, , Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ana Beatriz Gago Veiga

Role: CONTACT

+34 915202416

Iris Fernández Lázaro

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ana Beatriz Gago Veiga

Role: primary

+34 915202416

Iris Fernández Lázaro

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

Gago-Veiga AB, Pagan J, Henares K, Heredia P, Gonzalez-Garcia N, De Orbe MI, Ayala JL, Sobrado M, Vivancos J. To what extent are patients with migraine able to predict attacks? J Pain Res. 2018 Sep 27;11:2083-2094. doi: 10.2147/JPR.S175602. eCollection 2018.

Reference Type RESULT
PMID: 30310310 (View on PubMed)

Pagan J, De Orbe MI, Gago A, Sobrado M, Risco-Martin JL, Mora JV, Moya JM, Ayala JL. Robust and Accurate Modeling Approaches for Migraine Per-Patient Prediction from Ambulatory Data. Sensors (Basel). 2015 Jun 30;15(7):15419-42. doi: 10.3390/s150715419.

Reference Type RESULT
PMID: 26134103 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3513

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Migraine in Adolescents
NCT05654012 RECRUITING NA